Question special
Moderator

I've read that a major advantage of your trial design was a government health policy mandating inclusion in the trial as a precondition for reimbursement of the intervention. The policy of only paying for an intervention with unknown risk/benefit if it is used in an RCT seems logical. What sort of advice can you share on duplicating this sort of innovative health policy in larger countries like the U.S.?